Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,966.00GBp
12:09pm EDT
Change (% chg)

23.00 (+1.18%)
Prev Close
1,943.00
Open
1,936.00
Day's High
1,967.00
Day's Low
1,925.00
Volume
594,626
Avg. Vol
703,308
52-wk High
2,703.00
52-wk Low
1,575.00

Select another date:

Thu, Apr 6 2017

RPT-BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

BRIEF-Jazz Pharma settles Xyrem patent litigation with Hikma Pharma

* Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation

BRIEF-Hikma sees 2017 revenue to be around $2.2 bln

* FY group revenue of $1,950 million, up 35% and up 39% in constant currency

BRIEF-Hikma signs licensing deal with Orion for asthma product

* Signed an exclusive licensing and distribution agreement with Orion Corporation Of Finland, for its new Easyhaler combination product

Takeda, Hikma clash again in D.C. Circuit over gout drug

Hikma Pharmaceuticals PLC is fighting back against a bid by Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates to revive a case in a Washington, D.C. federal appeals court in order to block Hikma from selling its gout drug Mitigare.

BRIEF-Hikma gets FDA nod for Sodium Oxybate oral solution

* Wholly owned US subsidiary, roxane has received an approval from US FDA for its Sodium Oxybate oral solution

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Hikma Pharmaceuticals sees FY group revenue to grow by about 35 pct

* In US, good demand across a number of products and new product launches has more than offset increased competition for certain products

BUZZ-Hikma: top Stoxx loser as HSBC cuts TP on DoJ market probe

** Hikma Pharma -c.7% in heavy vols, biggest loser on Stoxx & trading at lowest in 10 mnths as HSBC cuts TP to 1985p from 2525p

Select another date:

More From Around the Web